10x Genomics Statistics
Total Valuation
10x Genomics has a market cap or net worth of $918.49 million. The enterprise value is $607.70 million.
Important Dates
The next confirmed earnings date is Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
10x Genomics has 122.30 million shares outstanding. The number of shares has increased by 2.81% in one year.
| Current Share Class | 108.25M |
| Shares Outstanding | 122.30M |
| Shares Change (YoY) | +2.81% |
| Shares Change (QoQ) | +0.72% |
| Owned by Insiders (%) | 8.44% |
| Owned by Institutions (%) | 89.05% |
| Float | 106.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.48 |
| Forward PS | 1.49 |
| PB Ratio | 1.29 |
| P/TBV Ratio | 1.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 137.83 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.99 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.97, with a Debt / Equity ratio of 0.12.
| Current Ratio | 4.97 |
| Quick Ratio | 4.09 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -48,114.75 |
Financial Efficiency
Return on equity (ROE) is -25.17% and return on invested capital (ROIC) is -14.77%.
| Return on Equity (ROE) | -25.17% |
| Return on Assets (ROA) | -12.77% |
| Return on Invested Capital (ROIC) | -14.77% |
| Return on Capital Employed (ROCE) | -24.03% |
| Revenue Per Employee | $467,676 |
| Profits Per Employee | -$139,837 |
| Employee Count | 1,306 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 2.50 |
Taxes
In the past 12 months, 10x Genomics has paid $4.93 million in taxes.
| Income Tax | 4.93M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -75.62% in the last 52 weeks. The beta is 2.01, so 10x Genomics's price volatility has been higher than the market average.
| Beta (5Y) | 2.01 |
| 52-Week Price Change | -75.62% |
| 50-Day Moving Average | 10.22 |
| 200-Day Moving Average | 15.87 |
| Relative Strength Index (RSI) | 36.75 |
| Average Volume (20 Days) | 3,523,517 |
Short Selling Information
The latest short interest is 12.06 million, so 9.86% of the outstanding shares have been sold short.
| Short Interest | 12.06M |
| Short Previous Month | 12.08M |
| Short % of Shares Out | 9.86% |
| Short % of Float | 11.37% |
| Short Ratio (days to cover) | 3.77 |
Income Statement
In the last 12 months, 10x Genomics had revenue of $610.79 million and -$182.63 million in losses. Loss per share was -$1.52.
| Revenue | 610.79M |
| Gross Profit | 414.78M |
| Operating Income | -192.46M |
| Pretax Income | -233.22M |
| Net Income | -182.63M |
| EBITDA | -156.58M |
| EBIT | -192.46M |
| Loss Per Share | -$1.52 |
Full Income StatementBalance Sheet
The company has $393.40 million in cash and $82.61 million in debt, giving a net cash position of $310.79 million or $2.54 per share.
| Cash & Cash Equivalents | 393.40M |
| Total Debt | 82.61M |
| Net Cash | 310.79M |
| Net Cash Per Share | $2.54 |
| Equity (Book Value) | 710.13M |
| Book Value Per Share | 5.81 |
| Working Capital | 466.75M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $6.66 million and capital expenditures -$12.39 million, giving a free cash flow of -$5.73 million.
| Operating Cash Flow | 6.66M |
| Capital Expenditures | -12.39M |
| Free Cash Flow | -5.73M |
| FCF Per Share | -$0.05 |
Full Cash Flow StatementMargins
Gross margin is 67.91%, with operating and profit margins of -31.51% and -29.90%.
| Gross Margin | 67.91% |
| Operating Margin | -31.51% |
| Pretax Margin | -29.09% |
| Profit Margin | -29.90% |
| EBITDA Margin | -25.64% |
| EBIT Margin | -31.51% |
| FCF Margin | n/a |
Dividends & Yields
10x Genomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.80% |
| Shareholder Yield | -2.80% |
| Earnings Yield | -19.88% |
| FCF Yield | -0.62% |
Dividend DetailsAnalyst Forecast
The average price target for 10x Genomics is $19.79, which is 163.52% higher than the current price. The consensus rating is "Buy".
| Price Target | $19.79 |
| Price Target Difference | 163.52% |
| Analyst Consensus | Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (5Y) | 6.68% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
10x Genomics has an Altman Z-Score of 7.44 and a Piotroski F-Score of 5.
| Altman Z-Score | 7.44 |
| Piotroski F-Score | 5 |